CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER (CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER).
Parenteral nutrition providing amino acids for protein synthesis, dextrose as a carbohydrate calorie source, and electrolytes to maintain physiologic homeostasis.
| Metabolism | Amino acids are metabolized via hepatic deamination and urea cycle; dextrose undergoes glycolysis and oxidative phosphorylation; electrolytes are handled via renal excretion and reabsorption. |
| Excretion | Amino acids: primarily renal as urea (via ureagenesis) and some as ammonia; dextrose: metabolized to CO2 and water, excreted via lungs and urine. Not applicable as combination product. |
| Half-life | Not applicable; components are endogenous substances. Amino acids have rapid clearance (minutes to hours) depending on metabolic demand; dextrose half-life ~1-2 hours in euglycemic state. |
| Protein binding | Minimal to moderate; amino acids: variable (e.g., tryptophan ~70-90% bound to albumin); dextrose: negligible. |
| Volume of Distribution | Amino acids: total body water (0.5-0.6 L/kg); dextrose: total body water (~0.5 L/kg). |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate rise in plasma amino acids and glucose levels within minutes. |
| Duration of Action | Depends on infusion rate and metabolic state; continuous infusion provides sustained levels. Effects persist as long as infusion continues. |
Intravenous infusion only. Dosing is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX 4.25/25, providing 4.25% amino acids and 25% dextrose. Infusion rate should not exceed 3 mg/kg/min for dextrose. Adjust for caloric and nitrogen requirements.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 50 mL/min: reduce total protein/amino acid intake to 0.6-0.8 g/kg/day; monitor electrolytes and fluid status. For dialysis patients: may require higher amino acid doses (1.2-1.5 g/kg/day) to offset losses. Adjust volume to avoid fluid overload. |
| Liver impairment | Child-Pugh Class B or C: reduce amino acid dose to 0.5-1.0 g/kg/day; avoid branched-chain amino acid (BCAA) enrichment unless specifically indicated (this product is not BCAA-enriched). Monitor for signs of encephalopathy. May need to restrict fluid if ascites present. |
| Pediatric use | Weight-based dosing: Initiate at 0.5-1 g amino acids/kg/day and increase gradually to 2-3 g/kg/day (max 4 g/kg/day) depending on age and condition. Dextrose infusion rate: start at 4-8 mg/kg/min, titrate to blood glucose goals. Total volume adjusted for fluid requirements (e.g., 100-150 mL/kg/day for neonates). |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER (CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER).
| Breastfeeding | Limited data; Clinimix components (amino acids, dextrose, electrolytes) are normal blood constituents and are likely transferred into breast milk in small amounts, not expected to cause adverse effects in infants. M/P ratio not established. Monitor infant for signs of gastrointestinal intolerance or hyperglycemia. Use with caution only when clearly needed. |
| Teratogenic Risk | Parenteral nutrition (PN) with Clinimix 4.25/25 (amino acids 4.25%, dextrose 25%) is generally considered necessary for maternal nutrition and fetal growth when oral/enteral intake is inadequate. No specific teratogenic effects are attributed to balanced amino acid and dextrose solutions at standard doses. However, risks may arise from improper composition (e.g., electrolyte imbalances, hyperglycemia) or underlying maternal malnutrition. First trimester: No known structural teratogenicity. Second/third trimesters: Risks relate to maternal metabolic control (e.g., hyperglycemia causing fetal macrosomia, neonatal hypoglycemia). Overall, use is indicated when benefit outweighs risks. |
■ FDA Black Box Warning
Not FDA-approved for use in children <2 years of age. Risk of aluminum toxicity with prolonged administration. Do not infuse simultaneously with blood products through the same administration set due to risk of hemolysis.
| Serious Effects |
["Hypersensitivity to any component of the formulation.","Hyperglycemia (diabetic coma, severe insulin resistance).","Severe electrolyte disturbances or metabolic acidosis.","Inborn errors of amino acid metabolism.","Severe hepatic failure or impending hepatic coma."]
| Precautions | ["Monitor for signs of infection, hyperglycemia, hypertriglyceridemia, and electrolyte imbalances.","Use with caution in patients with renal impairment, hepatic insufficiency, or metabolic disorders.","Aluminum toxicity risk in patients with impaired renal function or long-term use.","Do not administer unless solution is clear and container is undamaged."] |
Loading safety data…
| Start at lower end of adult dose range due to potential reduced renal function, altered glucose tolerance, and fluid shifts. Monitor renal function, blood glucose, and fluid balance closely. Typically 1-1.5 L/day initially, adjusting for comorbidities and metabolic needs. Avoid rapid infusion to prevent hyperglycemia and volume overload. |
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, renal function, liver function, acid-base status, serum osmolality, and nitrogen balance. Fetal monitoring via ultrasonography for growth and amniotic fluid volume, especially with prolonged use. In third trimester, assess for fetal macrosomia. |
| Fertility Effects | No direct impairment of fertility reported. Malnutrition itself can cause infertility; adequate PN may restore fertility. No studies on direct effect of PN components on gametes or reproductive function. |